Merck announces positive CHMP opinion for kidney cancer treatment after muted trading session

Merck announces positive CHMP opinion for kidney cancer treatment after muted trading session
Merck stock falls to $146.93

Merck received a positive opinion from the European Union's CHMP for a new combination treatment aimed at certain kidney cancer patients, with the development first announced on October 19, 2026. Separately, the stock edges lower on the day, trading at $146.93.

MRK price prediction
24H -0.21%
€149.83
48H -0.77%
€149
7D -0.47%
€149.45
1M 4.68%
€157.18
3M 13.59%
€170.56
6M 2.92%
€154.53
12M 25.86%
€188.98
Current price: €150.15 0.4500 0.30%
Closed 11/17
Daily range 149.20 Arrow from to Icon 151.40
Weekly range 144.60 Arrow from to Icon 156.20
Loading...

Highlights

  • Merck received a positive EU CHMP opinion for the Welireg-lenvatinib combination in advanced kidney cancer, reducing progression or death risk by 26% versus cabozantinib.
  • 77 of 110 analysts rate Merck stock a buy, with a $163 median target about 10.9% above the current $146.93 price.
  • Merck stock edges lower on the day, trading at $146.93.

The positive CHMP opinion was first announced on October 19, 2026. Merck announced a positive CHMP opinion for a potential new combination treatment for certain people with kidney cancer in the European Union. According to Rallies, the Welireg-lenvatinib combination reduced the risk of disease progression or death by 26% versus cabozantinib, although overall survival improvement was not statistically significant.

Bullish structure stays intact as market reaction remains subdued

Price is sitting right at support from the Ichimoku Kijun at $146.45. That support holds significance as shares remain above the MA-20, MA-50, and MA-200, preserving a bullish structure on the daily chart. The market has shown a muted reaction, with movements constrained against the prevailing upward bias.

Upside probability dominates as price consolidates above key support

Traders should watch for whether price stays above or drops below the Ichimoku Kijun at $146.45 to assess if the latest development is being absorbed. Price is currently testing this support level without a decisive break. The move has been contained within a narrow range over the past week, but from here, the probability of an upside move over the next five trading days stands at 74%, with a 26% chance of a downside move and an expected trading range of $145.13 to $148.72. A close above $149.31 would confirm buyers are willing to follow through, while a drop below $146.45 would indicate the move is being faded. On the weekly chart, the longer-term picture stays firmly constructive.

Previously it was reported that Merck initiated a major phase 3 clinical trial targeting the prevention of COPD exacerbations in adults with a history of flare-ups. The current positive CHMP opinion for a new kidney cancer combination treatment adds a fresh catalyst to the pipeline, and traders should monitor whether shares can maintain support above the Ichimoku Kijun level at $146.45 for early signs of directional momentum.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.